About benitec biopharma - BNTC
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
BNTC At a Glance
Benitec Biopharma, Inc.
3940 Trust Way
Hayward, California 94545
| Phone | 1-510-780-0819 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -37,917,000.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
BNTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.157 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.896 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
BNTC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,995,631.579 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BNTC Liquidity
| Current Ratio | 54.671 |
| Quick Ratio | 54.671 |
| Cash Ratio | 54.305 |
BNTC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -49.956 |
| Return on Equity | -52.465 |
| Return on Total Capital | -38.634 |
| Return on Invested Capital | -52.286 |
BNTC Capital Structure
| Total Debt to Total Equity | 0.873 |
| Total Debt to Total Capital | 0.865 |
| Total Debt to Total Assets | 0.852 |
| Long-Term Debt to Equity | 0.509 |
| Long-Term Debt to Total Capital | 0.504 |